Technical Analyst, Deepak Mohoni is of the view that one can sell Ranbaxy Laboratories.

Mohoni told CNBC-TV18, "Ranbaxy Laboratories is a sell and not really a buy because the stock has never really been able to catch up with its 2004 peak. It is slowly eroding throughout the entire bull market. It looks like it was making a bit of a move in the last few months but now it looks like it has sort of top towered for the year. It’s looking fairly weak. On market decline it’s a good short sell and for the portfolio the stock shouldn’t really be in there."

Disclosure: Analyst doesn't hold the above stock.